Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.

Newcorn JH, Stein MA, Cooper KM.

J Child Adolesc Psychopharmacol. 2010 Jun;20(3):187-96. doi: 10.1089/cap.2009.0102.

PMID:
20578931
2.

Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.

Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):663-71. doi: 10.1089/cap.2009.0033.

3.

Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.

Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D'souza DN, Schuh LM, Allen AJ.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1165-72. doi: 10.1097/CHI.0b013e3181bc730d.

PMID:
19858759
4.

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.

Faraone SV, Buitelaar J.

Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353-64. doi: 10.1007/s00787-009-0054-3. Epub 2009 Sep 10.

PMID:
19763664
5.

Comparative-effectiveness research--implications of the Federal Coordinating Council's report.

Conway PH, Clancy C.

N Engl J Med. 2009 Jul 23;361(4):328-30. doi: 10.1056/NEJMp0905631. Epub 2009 Jun 30. No abstract available.

6.

Does comparative-effectiveness research threaten personalized medicine?

Garber AM, Tunis SR.

N Engl J Med. 2009 May 7;360(19):1925-7. doi: 10.1056/NEJMp0901355. No abstract available.

7.

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.

Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD.

J Child Psychol Psychiatry. 2009 Mar;50(3):335-42. doi: 10.1111/j.1469-7610.2008.01960.x.

PMID:
19309330
8.

Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.

Daughton JM, Kratochvil CJ.

J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):240-8. doi: 10.1097/CHI.0b013e318197748f. Review. No abstract available.

PMID:
19242289
9.

Stimulant dosing for children with ADHD: a medical claims analysis.

Olfson M, Marcus S, Wan G.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):51-9. doi: 10.1097/CHI.0b013e31818b1c8f.

PMID:
19218896
10.

Using long-acting stimulants: does it change ADHD treatment outcome?

Swanson JM, Hechtman L.

Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):2-3.

11.

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing.

Circulation. 2008 May 6;117(18):2407-23. doi: 10.1161/CIRCULATIONAHA.107.189473. Epub 2008 Apr 21. No abstract available. Erratum in: Circulation. 2009 Aug 18;120(7):e55-9.

12.

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group.

Am J Psychiatry. 2008 Jun;165(6):721-30. doi: 10.1176/appi.ajp.2007.05091676. Epub 2008 Feb 15.

PMID:
18281409
13.

Remission versus response as the goal of therapy in ADHD: a new standard for the field?

Steele M, Jensen PS, Quinn DM.

Clin Ther. 2006 Nov;28(11):1892-908. Review.

PMID:
17213010
14.

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.

Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T.

J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1284-93. Erratum in: J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):141.

PMID:
17023867
15.

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H.

J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):817-23.

PMID:
16832318
16.

Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.

Biederman J, Gao H, Rogers AK, Spencer TJ.

Biol Psychiatry. 2006 Nov 15;60(10):1106-10. Epub 2006 Jun 27.

PMID:
16806096
17.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
18.

A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD.

Pliszka SR, Lopez M, Crismon ML, Toprac MG, Hughes CW, Emslie GJ, Boemer C.

J Am Acad Child Adolesc Psychiatry. 2003 Mar;42(3):279-87.

PMID:
12595780
19.

Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.

Faraone SV, Biederman J, Roe C.

J Clin Psychopharmacol. 2002 Oct;22(5):468-73.

PMID:
12352269
20.

Supplemental Content

Support Center